2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.

Fiche du document

Auteurs
Date

2015

Types de document
Périmètre
Langue
Identifiants
Source

Serveur académique Lausannois

Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1093/annonc/mdv187

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/25897013

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1569-8041

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_EFBB910B02B71

Collection

Serveur Académique Lausannois

Organisation

Université de Lausanne et CHUV

Licences

info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer

Mots-clés 0

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Bronchoscopy; Carboplatin/administration & dosage; Carcinoma, Non-Small-Cell Lung/diagnosis; Carcinoma, Non-Small-Cell Lung/pathology; Chemotherapy, Adjuvant; Cisplatin/administration & dosage; Disease Management; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Etoposide/administration & dosage; Europe; Humans; Lung/pathology; Lung/radiography; Lung Neoplasms/diagnosis; Lung Neoplasms/pathology; Lymph Nodes/pathology; Mediastinum; Multimodal Imaging; Pneumonectomy; Positron-Emission Tomography; Radiotherapy, Adjuvant; Societies, Medical; Tomography, X-Ray Computed; Vinblastine/administration & dosage; Vinblastine/analogs & derivatives

Sujets proches En

Lung cancer illness

Citer ce document

W.E. Eberhardt et al., « 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. », Serveur académique Lausannois, ID : 10.1093/annonc/mdv187

Métriques

Partage / Export

Résumé 0

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on locally advanced disease.

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Exporter en